AbbVie already has a working relationship with Gilgamesh, in the form of an R&D collaboration and opt-in licensing agreement ...

AbbVie Inc (ABBV) is reportedly negotiating to buy Gilgamesh Pharmaceuticals, a private company focusing on mental health treatments, for roughly $1 billion. The discussions, highlighted by Bloomberg, ...

AbbVie Inc. (NYSE: ABBV) is reportedly negotiating the acquisition of Gilgamesh Pharmaceuticals, a privately held mental ...

Gilgamesh is developing what are known as neuroplastogens, a type of next-generation psychedelic compound. A deal would ...

(Reuters) -Drugmaker AbbVie is in talks to acquire privately-held mental health therapeutics company Gilgamesh ...

Drugmaker AbbVie is in talks to acquire privately-held mental health therapeutics company Gilgamesh Pharmaceuticals in a deal ...

Q2 earnings set for July 31 with EPS up 9.8% YoY. Revenue to grow 3.9%. Discover key updates on its portfolio, guidance & M&A ...

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of ...

AbbVie on Wednesday said the Phase 3 study evaluating the safety and efficacy of Rinvoq in adults and adolescents with severe alopecia areata met its primary endpoint of 80% or more scalp hair ...

Over the past five years, ABBV has experienced a negative one-day return following its earnings announcements in 65% of ...

AbbVie's trading session ended on a bearish note, with shares dipping to $187.64, nearly $4 below the day's high. The stock ...